PAVmed subsidiary Lucid Diagnostics closes $28.75M stock offering at $1.00/share

PAVmed Inc.

Lucid Diagnostics sold 28.75M shares at $1.00 each via underwritten offering.
Underwriters' option for 3.75M shares exercised in full at closing.
Net proceeds expected to be approximately $26.9 million after expenses.
Funds to be used for working capital and general corporate purposes.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.